Cargando…

The different predictive effects of the intensity and proportion of CD20 expression on the prognosis of B‐lineage acute lymphocyte leukemia

The prognostic effects of the CD20 positivity have been studied extensively in B‐lineage acute lymphocyte leukemia (B‐ALL) patients, but the results remain controversial. The aim of this study is to investigate the different predictive effects of the intensity and proportion of CD20 expression on th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Yun, Wang, Xiaojiao, Ai, Hao, Lyu, Xiaodong, Wang, Qian, Wei, Xudong, Song, Yongping, Yin, Qingsong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Haematologic Malignancy ‐ Myeloid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176059/ https://www.ncbi.nlm.nih.gov/pubmed/35846053 http://dx.doi.org/10.1002/jha2.414

Ejemplares similares

Prophylaxis with low dose tranexamic acid in acute myeloid leukemia patients undergoing intensive chemotherapy
por: Bønløkke, Søren Thorgaard, et al.
Publicado: (2023)

DNA methylation analysis improves the prognostication of acute myeloid leukemia
por: Samimi, Hanie, et al.
Publicado: (2021)

Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada
por: Cressman, Sonya, et al.
Publicado: (2020)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Increased body mass index is a risk factor for acute promyelocytic leukemia
por: Kashanian, Sarah M., et al.
Publicado: (2021)

Molecular characteristics and outcomes in Hispanic and non‐Hispanic patients with acute myeloid leukemia
por: Bradley, Terrence, et al.
Publicado: (2022)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
por: Liu, Qingguo, et al.
Publicado: (2020)

De‐escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open‐label, prospective trial in China
por: Luo, Jie, et al.
Publicado: (2022)

Acute leukemias in pregnant women: Results of a retrospective study at a local tertiary‐care hospital in Japan
por: Kobayashi, Shuhei, et al.
Publicado: (2023)

Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect(®) MDS/AML Disease Registry
por: Pollyea, Daniel A., et al.
Publicado: (2020)

Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions
por: Patel, Shyam A., et al.
Publicado: (2023)

GSK3 inhibitor enhances gemtuzumab ozogamicin‐induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance
por: Inase, Aki, et al.
Publicado: (2022)

Efficacy analysis of different FLT3 inhibitors in patients with relapsed/refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome
por: Swaminathan, Mahesh, et al.
Publicado: (2022)

Models of care for chronic myeloid leukemia patients during the COVID‐19 pandemic in the United Kingdom: Changes in patient attitudes to remote consultations and future implications
por: Duncan, Nicholas, et al.
Publicado: (2021)

Fatal renal diseases among patients with hematological malignancies: A population‐based study
por: Li, Sen, et al.
Publicado: (2020)

Predictors of vascular disease in myelodysplastic syndromes
por: Faber, Mark G., et al.
Publicado: (2020)

Higher RUNX1 expression levels are associated with worse overall and leukaemia‐free survival in myelodysplastic syndrome patients
por: Wang, Yu‐Hung, et al.
Publicado: (2022)

Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers
por: Hernlund, Emma, et al.
Publicado: (2021)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
por: Ishida, Hisashi, et al.
Publicado: (2020)

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies
por: How, Joan, et al.
Publicado: (2022)

Single cell proteogenomic sequencing identifies a relapse‐fated AML subclone carrying FLT3‐ITD with CN‐LOH at chr13q
por: Kim, TaeHyung, et al.
Publicado: (2022)

Bimodal expression of RHOH during myelomonocytic differentiation: Implications for the expansion of AML differentiation therapy
por: Galiègue‐Zouitina, Sylvie, et al.
Publicado: (2021)

PD1 expression on bone marrow T‐cells in newly diagnosed Egyptian AML patients: Correlation with hematological parameters, aberrant antigens expression, and response to induction therapy
por: Bassiouny, Noha, et al.
Publicado: (2020)

Longitudinal trends of peripheral blood counts in polycythaemia vera and essential thrombocythemia patients in the UK
por: Carpenter, Lewis, et al.
Publicado: (2022)

Heterogeneous genetic and non‐genetic mechanisms contribute to response and resistance to azacitidine monotherapy
por: Symeonidou, Vasiliki, et al.
Publicado: (2022)

Increased prescription rate of anti‐infective agents after diagnosis of myelodysplastic syndromes
por: Rozema, Johanne, et al.
Publicado: (2022)

Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NCT05074706)
por: Bossi, Elisa, et al.
Publicado: (2022)

Germline RUNX1 variants in paediatric patients in a French specialised centre
por: Liu, Cécile, et al.
Publicado: (2022)

Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study
por: Ayala, Rosa, et al.
Publicado: (2023)

Incidence of blast phase in myelofibrosis according to anemia severity
por: Mora, Barbara, et al.
Publicado: (2023)

The JAK2(V617F) mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
por: Orbell, Lai Yee, et al.
Publicado: (2023)

A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab
por: Sawas, Ahmed, et al.
Publicado: (2017)

Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
por: Sharman, Jeff P., et al.
Publicado: (2016)

Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model
por: Gassner, Franz J, et al.
Publicado: (2015)

Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia
por: Huang, Ying‐Jung, et al.
Publicado: (2019)

Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia
por: Robak, Tadeusz, et al.
Publicado: (2016)

The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
por: Van Dyke, Daniel L., et al.
Publicado: (2016)

Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma
por: Holtan, Shernan G, et al.
Publicado: (2006)

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials
por: Jones, Jeffrey, et al.
Publicado: (2018)

Diagnosis of intravascular large B cell lymphoma: novel insights into clinicopathological features from 42 patients at a single institution over 20 years
por: Matsue, Kosei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1p9k0h661t6utqisornra545vp